跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
找到 202 条关于
“NEK7/NLRP3”
全部
202
临床试验
50
药物
47
机构
1
资讯
104
2年前
Halia Therapeutics Presents Phase II Data on HT-6184 for Post-Procedural Inflammation and Pain
去年
Halia Therapeutics Completes Enrollment in Phase 2a Trial of Novel NLRP3 Inflammasome Inhibitor for Myelodysplastic Syndrome
2年前
Halia Therapeutics Initiates Phase 2a Trial of First-in-Class NLRP3 Inhibitor HT-6184 for Lower-Risk Myelodysplastic Syndromes
4年前
NEK7 Emerges as Promising Inflammasome Target Despite Novartis Study Raising Questions About Universal Requirement
去年
Halia Therapeutics Presents LRRK2 Inhibitor HT-4253 for Neurodegenerative Diseases at BIO Investor Forum
去年
Halia Therapeutics Doses First Healthy Volunteer with Oral LRRK2 Inhibitor HT-4253 for Alzheimer's
去年
Halia Therapeutics Secures Novo Nordisk Golden Ticket for Innovative Obesity and Inflammation Research
去年
Monte Rosa Therapeutics Receives FDA Clearance for MRT-8102, First NEK7-Targeted Molecular Glue Degrader for Inflammatory Diseases
8个月前
Monte Rosa's MRT-8102 Demonstrates 85% Reduction in Cardiovascular Inflammation Marker in Phase 1 Trial
4个月前
Halia Therapeutics Reports 67% Hematological Improvement Rate with Ofirnoflast in Lower-Risk MDS Phase 2 Trial
第 1 页,共 11 页
上一页
下一页